115 related articles for article (PubMed ID: 38482706)
21. Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension.
La Mura V; Reverter JC; Flores-Arroyo A; Raffa S; Reverter E; Seijo S; Abraldes JG; Bosch J; García-Pagán JC
Gut; 2011 Aug; 60(8):1133-8. PubMed ID: 21427197
[TBL] [Abstract][Full Text] [Related]
22. Placental growth factor levels neither reflect severity of portal hypertension nor portal-hypertensive gastropathy in patients with advanced chronic liver disease.
Simbrunner B; Stadlmann A; Schwabl P; Paternostro R; Bauer DJM; Bucsics T; Scheiner B; Lampichler K; Wöran K; Beer A; Eigenbauer E; Pinter M; Stättermayer AF; Marculescu R; Szekeres T; Trauner M; Mandorfer M; Reiberger T
Dig Liver Dis; 2021 Mar; 53(3):345-352. PubMed ID: 33032973
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of von Willebrand factor in adult patients with congenital heart disease.
Ohuchi H; Hayama Y; Miike H; Suzuki D; Nakajima K; Iwasa T; Konagai N; Sakaguchi H; Miyazaki A; Shiraishi I; Kurosaki KI; Nakai M
Heart; 2020 Jun; 106(12):910-915. PubMed ID: 32188625
[TBL] [Abstract][Full Text] [Related]
24. The systemic and hepatic alternative renin-angiotensin system is activated in liver cirrhosis, linked to endothelial dysfunction and inflammation.
Hartl L; Rumpf B; Domenig O; Simbrunner B; Paternostro R; Jachs M; Poglitsch M; Marculescu R; Trauner M; Reindl-Schwaighofer R; Hecking M; Mandorfer M; Reiberger T
Sci Rep; 2023 Jan; 13(1):953. PubMed ID: 36653504
[TBL] [Abstract][Full Text] [Related]
25. Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease.
Scheiner B; Steininger L; Semmler G; Unger LW; Schwabl P; Bucsics T; Paternostro R; Ferlitsch A; Trauner M; Reiberger T; Mandorfer M
Liver Int; 2019 Jan; 39(1):127-135. PubMed ID: 30107095
[TBL] [Abstract][Full Text] [Related]
26. An impaired pituitary-adrenal signalling axis in stable cirrhosis is linked to worse prognosis.
Hartl L; Simbrunner B; Jachs M; Wolf P; Bauer DJM; Scheiner B; Balcar L; Semmler G; Schwarz M; Marculescu R; Trauner M; Mandorfer M; Reiberger T
JHEP Rep; 2023 Aug; 5(8):100789. PubMed ID: 37484210
[TBL] [Abstract][Full Text] [Related]
27. The VITRO Score (Von Willebrand Factor Antigen/Thrombocyte Ratio) as a New Marker for Clinically Significant Portal Hypertension in Comparison to Other Non-Invasive Parameters of Fibrosis Including ELF Test.
Hametner S; Ferlitsch A; Ferlitsch M; Etschmaier A; Schöfl R; Ziachehabi A; Maieron A
PLoS One; 2016; 11(2):e0149230. PubMed ID: 26895398
[TBL] [Abstract][Full Text] [Related]
28. von Willebrand factor as a novel noninvasive predictor of portal hypertension and esophageal varices in hepatitis B patients with cirrhosis.
Wu H; Yan S; Wang G; Cui S; Zhang C; Zhu Q
Scand J Gastroenterol; 2015; 50(9):1160-9. PubMed ID: 25877661
[TBL] [Abstract][Full Text] [Related]
29. Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes.
Jachs M; Hartl L; Schaufler D; Desbalmes C; Simbrunner B; Eigenbauer E; Bauer DJM; Paternostro R; Schwabl P; Scheiner B; Bucsics T; Stättermayer AF; Pinter M; Trauner M; Mandorfer M; Reiberger T
Gut; 2021 Sep; 70(9):1758-1767. PubMed ID: 33199442
[TBL] [Abstract][Full Text] [Related]
30. Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD.
Scheiner B; Balcar L; Nussbaumer RJ; Weinzierl J; Paternostro R; Simbrunner B; Hartl L; Jachs M; Bauer D; Stättermayer AF; Semmler G; Pinter M; Ay C; Quehenberger P; Trauner M; Reiberger T; Lisman T; Mandorfer M
J Hepatol; 2022 May; 76(5):1090-1099. PubMed ID: 35066090
[TBL] [Abstract][Full Text] [Related]
31. von Willebrand factor as a biomarker of clinically significant portal hypertension and severe portal hypertension: a systematic review and meta-analysis.
Zou Z; Yan X; Li C; Li X; Ma X; Zhang C; Ju S; Tian J; Qi X
BMJ Open; 2019 Aug; 9(8):e025656. PubMed ID: 31473610
[TBL] [Abstract][Full Text] [Related]
32. Alpha-1 antitrypsin Pi∗Z allele is an independent risk factor for liver transplantation and death in patients with advanced chronic liver disease.
Balcar L; Scheiner B; Urheu M; Weinberger P; Paternostro R; Simbrunner B; Hartl L; Jachs M; Bauer D; Semmler G; Willheim C; Pinter M; Ferenci P; Trauner M; Reiberger T; Stättermayer AF; Mandorfer M
JHEP Rep; 2022 Nov; 4(11):100562. PubMed ID: 36176936
[TBL] [Abstract][Full Text] [Related]
33. The von Willebrand Factor Facilitates Model for End-Stage Liver Disease-Independent Risk Stratification on the Waiting List for Liver Transplantation.
Györi GP; Pereyra D; Rumpf B; Hackl H; Köditz C; Ortmayr G; Reiberger T; Trauner M; Berlakovich GA; Starlinger P
Hepatology; 2020 Aug; 72(2):584-594. PubMed ID: 31773739
[TBL] [Abstract][Full Text] [Related]
34. Red cell distribution width/platelet ratio estimates the 3-year risk of decompensation in Metabolic Dysfunction-Associated Steatotic Liver Disease-induced cirrhosis.
Dallio M; Romeo M; Vaia P; Auletta S; Mammone S; Cipullo M; Sapio L; Ragone A; Niosi M; Naviglio S; Federico A
World J Gastroenterol; 2024 Feb; 30(7):685-704. PubMed ID: 38515952
[TBL] [Abstract][Full Text] [Related]
35. Disturbances in sodium and chloride homeostasis predict outcome in stable and critically ill patients with cirrhosis.
Semmler G; Scheiner B; Balcar L; Paternostro R; Simbrunner B; Pinter M; Trauner M; Bofill Roig M; Meyer EL; Hofer BS; Mandorfer M; Pinato DJ; Zauner C; Reiberger T; Funk GC
Aliment Pharmacol Ther; 2023 Jul; 58(1):71-79. PubMed ID: 37016513
[TBL] [Abstract][Full Text] [Related]
36. Bacterial translocation occurs early in cirrhosis and triggers a selective inflammatory response.
Simbrunner B; Caparrós E; Neuwirth T; Schwabl P; Königshofer P; Bauer D; Marculescu R; Trauner M; Scheiner B; Stary G; Mandorfer M; Reiberger T; Francés R
Hepatol Int; 2023 Aug; 17(4):1045-1056. PubMed ID: 36881247
[TBL] [Abstract][Full Text] [Related]
37. Serum keratin 19 (CYFRA21-1) links ductular reaction with portal hypertension and outcome of various advanced liver diseases.
Hamesch K; Guldiken N; Aly M; Hüser N; Hartmann D; Rufat P; Ziol M; Remih K; Lurje G; Scheiner B; Trautwein C; Mandorfer M; Reiberger T; Mueller S; Bruns T; Nahon P; Strnad P
BMC Med; 2020 Nov; 18(1):336. PubMed ID: 33176798
[TBL] [Abstract][Full Text] [Related]
38. Systematic review: role of elevated plasma von-Willebrand factor as predictor of mortality in patients with chronic liver disease.
Eidelberg A; Kirubakaran R; Nair SC; Eapen CE; Elias E; Goel A
Eur J Gastroenterol Hepatol; 2019 Oct; 31(10):1184-1191. PubMed ID: 31498279
[TBL] [Abstract][Full Text] [Related]
39. Non-invasive tests for clinically significant portal hypertension after HCV cure.
Semmler G; Lens S; Meyer EL; Baiges A; Alvardo-Tapias E; Llop E; Tellez L; Schwabl P; Mauro E; Escudé L; Díez C; Ibañez-Samaniego L; Puente Á; Fortea JI; Abadía M; Zanetto A; Conthe A; Hernandez-Évole H; Luzko Scheid IS; Jia J; Yoshiji H; Francque SM; Tsochatzis EA; Russo FP; Crespo G; Forns X; Bañares R; Villanueva C; Hernández-Gea V; Reiberger T; Bosch J; García Pagán JC; Mandorfer M;
J Hepatol; 2022 Dec; 77(6):1573-1585. PubMed ID: 36063968
[TBL] [Abstract][Full Text] [Related]
40. Vitamin A levels reflect disease severity and portal hypertension in patients with cirrhosis.
Simbrunner B; Semmler G; Stadlmann A; Scheiner B; Schwabl P; Paternostro R; Bucsics T; Bauer D; Eigenbauer E; Pinter M; Stättermayer AF; Quehenberger P; Marculescu R; Trauner M; Mandorfer M; Reiberger T
Hepatol Int; 2020 Dec; 14(6):1093-1103. PubMed ID: 33289910
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
